Sold out

Signaling Networks, Cell Cycle Control, and Human Cancer

English · Hardback

Description

Read more

The past few decades have witnessed scientists gaining a considerable understanding of the molecular pathogenesis of human diseases, especially of cancer. Studies of the molecular basis of carcinogenesis have led to the realization that cancer is fundamentally a disease of genetic alterations. The multiple genetic changes in cancer are predominantly the result of accumulating mutations that have occurred in the genome over time. These genetic changes lead to the production of gene products with upreguated, repressed, or loss of function, which in turn produce aberrant signal transduction pathways and dysregulated cellular functions. The bulk of evidence demonstrates that dysregulated signal transduction pathways promote malignant transformation and support the formation, maintenance and progression of tumors. The initial discovery of viral oncogenes and how these oncogenes could induce malignant transformation, in part by dysregulating growth and survival pathways, has provided us with a strong link between aberrant signal transduction and tumorigenesis. Studies subsequently identified cellular counterparts of oncogenes, called proto-oncogenes, and noted that the functions of these become dysregulated in response to oncogenes and activating mutations harbored in these proto-oncogenes. The presence of activating mutations in proto-oncogenes have been linked to aberrations in signaling intermediates, in turn leading to a perturbed signaling network that drives uncontrolled cell growth and survival, migration, invasion and metastasis, and promoting new blood vessel formation, as well as suppressing tumor immune surveillance. Indeed many human tumors harbor activatingmutations in cellular proto-oncogenes. Multiple molecular alterations in genesa "amplifications, overexpression and/or activating mutationsa "have been found in human tumors that code for proteins with constitutive activity, such as Ras family Gproteins, growth factors and receptors, and tyrosine kinases. Furthermore, tumors with loss-of-function mutations in p53 tumor suppressor gene and others alike have been detected. These critical mutations that create dysfunctional proteins or lead to loss of function of important regulatory proteins permanently alter cellular signaling network and promote cellular behavior consistent with malignant transformation, including anchorage-independent growth and loss of contact inhibition, factor-independent growth, uncontrolled cell cycle, and the possession of survival advantage.

Product details

Assisted by ERI (Editor), Haura Eric (Editor), Turkso (Editor), James Turkson (Editor)
Publisher Springer Nature Singapore
 
Languages English
Product format Hardback
Released 01.07.2008
 
No. of pages 450
Series Cancer Drug Discovery & Develo
Cancer Drug Discovery & Develo
Subject Natural sciences, medicine, IT, technology > Medicine > Non-clinical medicine

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.